# US 11,440,959 B2 · CD226 agonist antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,440,959 B2
- Document ID: US11440959B2
- Status: Granted
- Kind: B2
- Application number: 16/500,947
- Filed: 2019-07-19
- Published: 2021-11-25
- Granted: 2022-09-13
- Earliest claimed: 2018-07-26
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Naresh Kumar
- Web page: https://patentgrep.com/patent/US11440959B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- A61K 2039/505: {comprising antibodies}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to anti-human CD226 agonist antibodies, which can be useful for treating solid tumor cancers.

## Claims

### Claim 1

An anti-human CD226 antibody, comprising an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence of SEQ ID NO: 5, and an LCDR3 having the amino acid sequence of SEQ ID NO: 6.

### Claim 2 (depends on 1)

The anti-human CD226 antibody of claim 1, comprising an HCVR having the amino acid sequence of SEQ ID NO: 7 and an LCVR having the amino acid sequence of SEQ ID NO: 8.

### Claim 3 (depends on 1)

The anti-human CD226 antibody of claim 1, comprising an HC having the amino acid sequence of SEQ ID NO: 9, and an LC having the amino acid sequence of SEQ ID NO: 10.

### Claim 4 (depends on 1)

The anti-human CD226 antibody of claim 1, consisting of two HCs having the amino acid sequence of SEQ ID NO: 9, and two LCs having the amino acid sequence of SEQ ID NO: 10.

### Claim 5

A pharmaceutical composition, comprising the anti-human CD226 antibody of 3, and an acceptable carrier, diluent, or excipient.

### Claim 6

A DNA molecule comprising a polynucleotide having the sequence of SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NOS: 11 and 12.

### Claim 7

A method of treating a solid tumor cancer, comprising administering to a patient in need thereof, an effective amount of the anti-human CD226 antibody of 3, wherein the solid tumor cancer is bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, soft tissue sarcoma, gastric cancer, testicular cancer, thyroid cancer, uterine cancer or urothelial cancer.